Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database

Página do item simplificado
dc.contributor.authorHan, Bing
dc.contributor.authorYao, Hui
dc.contributor.authorShao, Lichun
dc.contributor.authorGuo, Xiaozhong
dc.contributor.authorHan, Lei
dc.contributor.authorRomeiro, Fernando Gomes [UNESP]
dc.contributor.authorMancuso, Andrea
dc.contributor.authorQi, Xingshun
dc.contributor.institutionGen Hosp Shenyang Mil Area
dc.contributor.institutionJinzhou Med Univ
dc.contributor.institution463 Hosp Chinese PLA
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionOsped Niguarda Ca Granda
dc.contributor.institutionAzienda Rilievo Nazl ad Alta Specializzaz Civ Di
dc.date.accessioned2018-11-26T17:52:06Z
dc.date.available2018-11-26T17:52:06Z
dc.date.issued2018-05-01
dc.description.abstractPurpose: To explore the selection of treatment modalities for hepatocellular carcinoma (HCC) at stages T1 and/or T2 and to compare the survival of patients treated with surgery alone vs radiation therapy (RT) alone. Methods: Surveillance, Epidemiology, and End Results (SEER) database was used to identify the patients diagnosed with HCC between 2004 and 2013. The tumor-node-metastasis (TNM) stage was established according to the American Joint Committee on Cancer (AJCC) Staging. After age, sex, TNM stage, and tumor extension were matched, the survival was further compared between patients undergoing surgery alone vs RT alone. Results: Of 11967 patients at stages T1 (n=7829) and T2 (n=4138), 10449 (87.31%) underwent surgery alone, 1241 (10.37%) RT alone, and 277 (2.32%) surgery combined with RT. Compared with those treated with RT alone and in combination with surgery, patients treated with surgery alone were younger, with smaller tumor size, higher proportion of females, single lesion, and AJCC stage I/II, and lower proportion of regional and distant lymph nodes, bone, brain, and lung invasion. Among them, 758 pairs (surgery alone and RT alone) at stage T1 and 430 pairs (surgery alone and RT alone) at stage T2 were matched. Regardless of stage T1 or T2, patients undergoing surgery alone had a significantly better cumulative survival than those undergoing RT alone (p<0.001). Conclusion: The treatment selection of HCC was dependent on the age, sex, tumor size, number of lesions, and extrahepatic invasion. Surgery alone should be the preferred treatment modality of HCC at stages T1 and T2.en
dc.description.affiliationGen Hosp Shenyang Mil Area, Dept Gastroenterol, 83 Wenhua Rd, Shenyang 1108410, Liaoning, Peoples R China
dc.description.affiliationJinzhou Med Univ, Postgrad Coll, Jinzhou, Liaoning, Peoples R China
dc.description.affiliation463 Hosp Chinese PLA, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China
dc.description.affiliationGen Hosp Shenyang Mil Area, Dept Hepatobiliary Surg, Shenyang, Liaoning, Peoples R China
dc.description.affiliationUniv Estadual Paulista UNESP, Dept Internal Med, Botucatu Med Sch, Av Prof Mario Rubens Guimaraes Montenegro S-N, BR-608917 Botucatu, SP, Brazil
dc.description.affiliationOsped Niguarda Ca Granda, Epatol & Gastroenterol, Milan, Italy
dc.description.affiliationAzienda Rilievo Nazl ad Alta Specializzaz Civ Di, Med Interna 1, Piazzale Leotta 4, I-90100 Palermo, Italy
dc.description.affiliationUnespUniv Estadual Paulista UNESP, Dept Internal Med, Botucatu Med Sch, Av Prof Mario Rubens Guimaraes Montenegro S-N, BR-608917 Botucatu, SP, Brazil
dc.description.sponsorshipNational Natural Science Foundation of China
dc.description.sponsorshipNatural Science Foundation of Liaoning Province
dc.description.sponsorshipChina Postdoctoral Science Foundation
dc.description.sponsorshipIdNational Natural Science Foundation of China: 81500474
dc.description.sponsorshipIdNatural Science Foundation of Liaoning Province: 2015020409
dc.description.sponsorshipIdChina Postdoctoral Science Foundation: 2015M582886
dc.format.extent611-621
dc.identifier.citationJournal Of Buon. Athens: Imprimatur Publications, v. 23, n. 3, p. 611-621, 2018.
dc.identifier.issn1107-0625
dc.identifier.urihttp://hdl.handle.net/11449/164317
dc.identifier.wosWOS:000435151300011
dc.language.isoeng
dc.publisherImprimatur Publications
dc.relation.ispartofJournal Of Buon
dc.relation.ispartofsjr0,420
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjecthepatocellular carcinoma
dc.subjectoutcome
dc.subjectradiation
dc.subjectsurgery
dc.subjecttreatment
dc.titleSelection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry databaseen
dc.typeArtigo
dcterms.rightsHolderImprimatur Publications

Arquivos

Coleções

Artigos - Clínica Médica - FMB